CD274 and glioblastoma: For instance, research in glioblastoma (GBM) has shown that PD-L1 blockade combined with a dendritic cell vaccine can deplete PD-L1+ macrophages, suppress myeloid inflammation, and enhance effector T cells, leading to significant disease regression (20).